• HOME |
  • SITE MAP |
  • CONTACT |
  • KOREAN
Product Search
since 1897 R&D visual

R&D

  • About R&D
  • Research Achievements
  • Organization of research institute
  • Key Research Area
  • R&D Pipeline
  • Technical Innovation Network
  • Global Dong Wha

Research Achievements

1973

  • The Central Research Center was established

1985

  • Completed the construction of the Central Research Center building
  • Commercialized Cefmetazone Injection, a freeze-dried injectable

1994

  • Won the IR52 Jang Young-shil Award (Successful development of Ambroxol)
  • Commercialized inflammatory analgesic Loxonin Tablet

2001

  • Succeeded in developing the world's first radiopharmaceutical to treat liver cancer, "Milican Injection"
  • Won the Dasan Technology Award
  • Obtained the Certificate for being a World-Class Korean Product

2002

  • "Milican Injection" included in "Top 10 New Technologies in Korea
  • Won the Korea New Drug Award
  • Won the Prime Minister Award for Industry-Academia Joint Research

2003

  • Commercialized Vitachun Plus
  • Won the Dongam Pharmaceutical Award (New Drug Development Category)
  • Received the Bronze Medal, the Order of Industrial Service Merit

2004

  • Succeeded in the synthesis of Pantoprazole (Gastric, duodenal ulcer treatment)

2007

  • Transferred the technology of osteoporosis treatment (DW1350) (P&GP, USA)
  • Transferred the technology of quinolone antimicrobial (DW224a) (Pacific Beach Biosciences, USA)

2008

  • Transferred the technology of osteoporosis treatment (DW1350) (Teijin, Japan)

2010

  • Completed the construction of the Yongin Research Center

2014

  • Released Clzapin in the domestic market (Independent localization)

2015

  • Zabolante received the NET certificate of the Ministry of Health and Welfare
  • Zabolante, a new quinolone antimicrobial, received the Ministry of Food and Drug Safety's approval

2016

  • Signed a license and supply contract for Zabolante with 12 countries in the Middle East and Africa

2017

  • Signed a license and supply (sales) contract for Zabolante with China

2018

  • Zabolante won the Korea New Drug Award
Go to TOP

6~8F, FastFive Tower, 24, Namdaemun-ro 9-gil, Jung-gu, Seoul, 04522, KOREA

Coptright(c) Dong Wha PHARM.CO.,LTD. All Rights Reserved.